Literature DB >> 11285263

Partial reconstitution of photoreceptor cGMP phosphodiesterase characteristics in cGMP phosphodiesterase-5.

A E Granovsky1, N O Artemyev.   

Abstract

Photoreceptor cGMP phosphodiesterases (PDE6) are uniquely qualified to serve as effector enzymes in the vertebrate visual transduction cascade. In the dark-adapted photoreceptors, the activity of PDE6 is blocked via tight association with the inhibitory gamma-subunits (Pgamma). The Pgamma block is removed in the light-activated PDE6 by the visual G protein, transducin. Transducin-activated PDE6 exhibits an exceptionally high catalytic rate of cGMP hydrolysis ensuring high signal amplification. To identify the structural determinants for the inhibitory interaction with Pgamma and the remarkable cGMP hydrolytic ability, we sought to reproduce the PDE6 characteristics by mutagenesis of PDE5, a related cyclic GMP-specific, cGMP-binding PDE. PDE5 is insensitive to Pgamma and has a more than 100-fold lower k(cat) for cGMP hydrolysis. Our mutational analysis of chimeric PDE5/PDE6alpha' enzymes revealed that the inhibitory interaction of cone PDE6 catalytic subunits (PDE6alpha') with Pgamma is mediated primarily by three hydrophobic residues at the entry to the catalytic pocket, Met(758), Phe(777), and Phe(781). The maximal catalytic rate of PDE5 was enhanced by at least 10-fold with substitutions of PDE6alpha'-specific glycine residues for the corresponding PDE5 alanine residues, Ala(608) and Ala(612). The Gly residues are adjacent to the highly conserved metal binding motif His-Asn-X-X-His, which is essential for cGMP hydrolysis. Our results suggest that the unique Gly residues allow the PDE6 metal binding site to adopt a more favorable conformation for cGMP hydrolysis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11285263     DOI: 10.1074/jbc.M100626200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

Review 1.  The retinal cGMP phosphodiesterase gamma-subunit - a chameleon.

Authors:  Lian-Wang Guo; Arnold E Ruoho
Journal:  Curr Protein Pept Sci       Date:  2008-12       Impact factor: 3.272

2.  Structural basis of phosphodiesterase 6 inhibition by the C-terminal region of the gamma-subunit.

Authors:  Brandy Barren; Lokesh Gakhar; Hakim Muradov; Kimberly K Boyd; S Ramaswamy; Nikolai O Artemyev
Journal:  EMBO J       Date:  2009-10-01       Impact factor: 11.598

3.  Determinants for phosphodiesterase 6 inhibition by its gamma-subunit.

Authors:  Zhongming Zhang; Nikolai O Artemyev
Journal:  Biochemistry       Date:  2010-05-11       Impact factor: 3.162

4.  Mechanisms of mutant PDE6 proteins underlying retinal diseases.

Authors:  Kota N Gopalakrishna; Kimberly Boyd; Nikolai O Artemyev
Journal:  Cell Signal       Date:  2017-06-02       Impact factor: 4.315

5.  Identification of amino acid residues responsible for the selectivity of tadalafil binding to two closely related phosphodiesterases, PDE5 and PDE6.

Authors:  Karyn B Cahill; Jonathan H Quade; Karen L Carleton; Rick H Cote
Journal:  J Biol Chem       Date:  2012-10-02       Impact factor: 5.157

6.  Characterization of human cone phosphodiesterase-6 ectopically expressed in Xenopus laevis rods.

Authors:  Hakim Muradov; Kimberly K Boyd; Mohammad Haeri; Vasily Kerov; Barry E Knox; Nikolai O Artemyev
Journal:  J Biol Chem       Date:  2009-09-28       Impact factor: 5.157

7.  It takes two transducins to activate the cGMP-phosphodiesterase 6 in retinal rods.

Authors:  Bilal M Qureshi; Elmar Behrmann; Johannes Schöneberg; Justus Loerke; Jörg Bürger; Thorsten Mielke; Jan Giesebrecht; Frank Noé; Trevor D Lamb; Klaus Peter Hofmann; Christian M T Spahn; Martin Heck
Journal:  Open Biol       Date:  2018-08       Impact factor: 6.411

Review 8.  Photoreceptor Phosphodiesterase (PDE6): Structure, Regulatory Mechanisms, and Implications for Treatment of Retinal Diseases.

Authors:  Rick H Cote; Richa Gupta; Michael J Irwin; Xin Wang
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.